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Background: This study aims to investigate the incidence and the relative risk factors of retinopathy of prematurity
(ROP) and posterior-ROP (P-ROP): ROP in Zone I and posterior Zone II, as well as to analyze the occurrence of
surgical treatment of ROP and to evaluate the short term outcome of the disease in Italy.
Methods: It is a prospective multicenter observational study; all infants with a birth weight (BW) ≤ 750 g and/or a
gestational age (GA) ≤27 weeks born between January 1st 2008 and December 31st 2009 in 25 III level Italian
neonatal intensive care units were eligible for the study.
Results: 421 infants were examined: 265 (62.9%) developed ROP and 102 (24.2%) P-ROP.
Following the multivariate analysis erythropoietin-therapy (p < 0.0001) and intraventricular hemorrhage (IVH)
(p = 0.003) were significantly associated with ROP while gestational age ≤24 weeks (p = 0.011) and sepsis (p = 0.002)
were associated with the onset of P-ROP. Eighty nine infants (34%) required surgical treatment; following the
multivariate analysis P-ROP was an independent factor associated with the need of surgical treatment (p < 0.0001).
A favorable outcome was reported in 251 (94.7%) newborns affected by ROP. Adverse outcome occurred in 14
patients: all of them underwent surgery and showed P-ROP.
Conclusions: P-ROP is the most aggressive type of ROP. It associates with lower GA and sepsis. Obstetricians and
Neonatologists must focus on the reduction of severe preterm births and on the prevention of neonatal early and
late onset sepsis in order to reduce the incidence of P-ROP.
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Retinopathy of prematurity (ROP) is a vasoproliferative
disorder of the retina that may result in a significant loss
of vision and even blindness. In recent decades the sur-
vival rate of extremely preterm infants has improved
dramatically [1]. Since extremely preterm infants are at
high risk of developing ROP, the number of infants with
severe ROP has risen considerably in the last few years.
Currently, ROP is one of the most common causes of
childhood blindness [2].
In 1951, Campbell first highlighted the involvement of
supplemental oxygen in the pathogenesis of ROP; the
role of oxygen was subsequently reconfirmed by other* Correspondence: cborroni@alice.it
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reproduction in any medium, provided the orauthors [3,4]. During the first stage of the pathogenesis
of ROP, hyperoxia suppresses the activity of the vascular
endothelial growth factor (VEGF) and alters the normal
vascularization of the retina due to vaso-constriction
and vaso-obliteration of the existing immature vessels.
In the second phase of ROP, upregulation of VEGF and
other growth factors, triggered by hypoxia, induces vascu-
lar overproliferation. Thus both hypoxia and hyperoxia are
involved in the pathogenesis of ROP [5].
Fifty percent of extremely preterm infants show clin-
ical signs of ROP, although this percentage varies widely.
Complete recovery rate is approximately 85% [6].
Several papers have described the risk factors for ROP
and have provided recommendations for the prevention of
the disease [7,8]. The American Academy of Pediatrics, the
American Academy of Ophthalmology and the American
Association of Pediatric Ophthalmology and StrabismusLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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rently used in neonatal intensive care units (NICUs)
[9-12]. According to these studies all preterm infants born
at less than 30 weeks of gestation and/or with a birth-
weight less than 1500 g should undergo an indirect oph-
thalmoscopy of dilated eyes. The ophthalmoscopy should
start from the 31st week of postconceptional age or from
the 28th day of life. The CRYO-ROP report has defined
the criteria of the “threshold ROP”; the ETROP data,
published in December 2003, demonstrated a benefit of
earlier treatment compared with conventional manage-
ment; babies who meet ETROP criteria should be con-
sidered eligible for surgical treatment (cryo-therapy,
argon or diode laser-therapy) [12,13].
The aim of our prospective multicenter cohort study is
to investigate the incidence and the relative risk factors
of ROP and P-ROP, the incidence of surgical treatment
and to evaluate the short-term outcome of the disease in
Italy.
Methods
This study, promoted by the “Italian ROP study group”,
involved a cohort of infants born between January 1st
2008 and December 31st 2009 with a birth weight
(BW) ≤ 750 g and/or a gestational age (GA) ≤27 weeks,
in 25 III level Italian NICUs. Gestational age was con-
firmed by fetal ultrasound. In order to reduce differences
in the neonatal assistance, the newborns admitted to the
III level NICUs 6 hours following birth were excluded;
newborns who died before discharge and newborns
affected by major congenital malformations were also
excluded.
The following data for each infants were recorded on a
specific database: gender, race, premature rupture of mem-
branes, chorioamnionitis, use of prenatal steroids, place of
birth (inborn or outborn), fifth minute Apgar score, days of
mechanical ventilation, days of parenteral nutrition, doses
of erythropoietin (EPO) and blood transfusions.
The following complications of preterm birth were
registered:
– intraventricular hemorrhage (IVH): any grade
according to the Volpe classification [14]
– periventricular leukomalacia (PVL): evaluated at
any age by ultrasounds (cystic periventricular white
matter lesions) or by Magnetic Resonance Imaging
(periventricular high-intensity areas on T2-weighted
images and atrophy of the cerebral white matter
predominantly at the peritrigonal region)
– respiratory distress syndrome (RDS): oxygen
requirement increasing during the first 24 hours,
typical radiological pattern such as reduced air
content, reticulogranular pattern of the lung air and
bronchogram– patent ductus arteriosus (PDA): clinical evidence of
left to right PDA shunt or ecocolorDoppler evidence
of PDA with evidence of left to right ductal shunting
– early or late onset sepsis:
 early: bacterial and/or fungal infections, diagnosed
by means of a positive culture of blood and/or
cerebrospinal fluid, within the first three days of life,
 late sepsis: if diagnosed, after the third day of life
– moderate or severe BPD, in accordance with the
definition of Jobe and Bancalari [15]
 moderate BPD is determined as the need for
< 30% oxygen at 36 week postmenstrual age
(PMA) or discharge whichever comes first
 severe BPD is determined as the need for
≥ 30% oxygen and/or positive pressure (NCPAP
or IPPV) at 36 week PMA or discharge
whichever comes first
This is a prospective non-interventional survey, the
participating neonatal intensive care unit assisted the
newborns in accordance with their own protocols; there-
fore the management and the care of the patients in
each center varied one from the other.
Only the eye examinations were standardized: all the
participating centers have a staff of pediatric ophthal-
mologists. Following pupil dilation with cyclopentolate
hydrochloride 0.2% and phenylephrine hydrochloride 1%,
pediatric ophthalmologists performed indirect ophthal-
moscopies using scleral depression, if required, to visualize
the retinal periphery, at weekly intervals, starting from
the 4th week of life until complete retinal vascularization
occurred [12].
Ophthalmologists diagnosed ROP according to the
ICROP report and classified the severity of ROP on the
basis of:
Zone:
– Posterior: ROP in Zone I and posterior Zone II
(P-ROP) [16]
– other zones: ROP in other Zones (OZ-ROP)
Presence of pre-plus (p-PD) or plus disease (PD) [12].
The classification based on Zone and on the presence
of plus or pre-plus disease was chosen in order to reduce
the variability in the classification of ROP among the
various centers participating in the trial.
In case of surgical intervention, ophthalmologists
reported the type of intervention carried out (Laser-ther-
apy, Cryo-therapy) and the number of ablative surgical
treatments performed. The outcome was defined “adverse”
if total or partial retinal detachment or macular fold oc-
curred, while normal anatomy (no detachment or macular
fold) was defined as “a favorable outcome”.
Univariate and multivariate logistic regression models
were used to estimate the odds ratios (ORs) and the
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ical parameters of the patients. Initially, the models
were used to evaluate the independent predicting fac-
tors for developing ROP of any stage; the independent
parameters associated with the evolution of the disease
were also studied. Moreover, ORs were used to describe
the characteristics of the infants that were candidates
for the laser treatment. Sample size was calculated to
detect a difference equal or greater than 15% in relative
frequencies of different groups, with 5% significance
level and a power of 80%.
A P value <0.05 was considered significant. All statistical
analysis was performed with Stata software 9.0 (Stata
Corporation, 1999, Texas, U.S.A.).
Results
The study involved 421 VPI; the spreadsheets were not
completed in full for each newborn, with a rate of in-
completeness for each parameter between 4% and 15%.
Birth weight, gestational age and ROP description were
considered mandatory, moreover newborns with more
than 10% missing data were not included in the sample.
Table 1 shows the distribution of birth weight and
gestational age, and the clinical features of the study
population.
All infants underwent the eye examinations in accord-
ance with the guidelines. Ophthalmological screening
was started at an average of 30 weeks of postmenstrual
age. ROP was diagnosed in 265 newborns (62.9%). At
the univariate analysis (Table 2) GA (p = 0.008), BW
(p = 0.007), PDA (p =0.002), IVH (p = 0.001), early andTable 1 Population characteristics
Parameters N° of newborns %
GA (weeks)
22–23 - 24 92 22.6%
25 102 24.2%
26 134 31.8%





> 750 175 41.6%
Male 182 45.5%
Inborn 358 88.0%
APGAR score 5th minute ≤ 7 176 47.7%
PROM 122 31.9%
Chorioamnionitis 93 27.8%
Antenatal steroids 331 84.0%late onset sepsis (p = 0.001), BPD (p = 0.002) and EPO
therapy (p < 0.001), showed a significant association
with the occurrence of ROP.
Following the multivariate analysis only EPO-therapy
(p < 0.0001) and IVH (p = 0.003) were significantly
associated with ROP (Table 3). P-ROP was diagnosed in
102 cases (24.2%); the ROP Zone was not reported in 10
cases; 7 of these infants underwent surgical treatment
and all of them had a favorable outcome (Figure 1).
Gestational age (p = 0.002), sepsis (p = 0.002) and BPD
(p = 0.02) were significantly associated with P-ROP. At the
multivariate analysis, gestational age ≤ 24 weeks (p = 0.011)
and sepsis (p =0.002) appeared to be independent factors
leading to P-ROP (Table 4).
PD was diagnosed in 79 newborns; 56 of them were
affected by P-ROP (55%) and 19 were affected by OZ-
ROP, (in 4 infants ROP Zone was not reported)
(Figure 1).
p-PD was diagnosed in 17 newborns with P-ROP, in
33 infants with OZ-ROP and in 5 patients the zone of
ROP was unknown (Figure 1). These differences were
statistically significant (p < 0.0001).
Eighty-nine infants underwent surgery (34% of the
265 newborns with ROP); 59 of them (66.3%) showed a
P-ROP and 23 (25.8%) an OZ-ROP (Figure 1). This
difference was statistically significant (p <0.0001).
Zone of ROP, gestational age, birth weight and sepsis
were significantly associated with need of surgery at the
univariate analysis; following the multivariate analysis
only P-ROP was an independent factor associated with





Fungal Sepsis 46 11.4%
Bacterial Sepsis 178 44.2%
BPD 208 54.9%
Blood transfusions 357 89.9%
EPO therapy 210 55.6%
Mechanical ventilation ( > 7 days) 258 69.2%
NPT ( > 7 days) 303 80.6%
ROP 265 62.9%
P - ROP 102 24.2%
Preplus disease 55 13.1%
Plus disease 79 18.8%
Laser treatment 89 21.1%
Adverse outcome 14 3.3%
Table 2 Association between ROP and neonatal parameters: logistic univariate analysis
Parameters ROP No ROP Univariate analysis
n newborns (%) OR p-value
GA ≤ 24 weeks 71 (75%) 24 (25%) 2.01 0.008
BW ≤ 750 g 168 (68%) 78 (32%) 1.73 0.007
Male gender 111 (45%) 71 (46%) 0.96 0.848
Inborn 217 (86%) 141 (90%) 0.68 0.238
APGAR score 5th minute ≤ 7 125 (56%) 72 (49%) 1.31 0.205
PROM 78 (34%) 44 (29%) 1.22 0.380
Chorioamnionitis 60 (31%) 33 (23%) 1.47 0.130
Antenatal steroids 198 (81%) 133 (88%) 0.59 0.085
RDS 234 (100%) 150 (100%) Not applicable
PDA 167 (66%) 84 (34%) 1.96 0.002
IVH 118 (71%) 49 (29%) 2.10 0.001
LPV 44 (19%) 55 (38%) 1.22 0.543
Sepsis 134 (70%) 57 (30%) 2.02 0.001
BPD 142 (61%) 66 (45%) 1.94 0.002
Blood transfusions 217 (90%) 140 (90%) 0.93 0.833
EPO therapy 147 (70%) 63 (30%) 2.39 < 0.0001
Mechanical ventilation (>7 days) 157 (71%) 101 (67%) 1.20 0.432
NPT ( > 7 days) 185 (83%) 118 (78%) 1.37 0.234
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while gestational age (p = 0.946) and sepsis (p = 0.188)
were not statistically related to the requirement of laser
therapy. The use of EPO was not associated with surgi-
cal treatment: 54% of the surgically treated infants and
68.2% of the non-treated infants received EPO.
PD was diagnosed in 87.5% of the surgically treated in-
fants and p-PD in 12.5% of cases. None of the newborns
without PD or p-PD underwent surgery. One hundred sev-
enty newborns with ROP were not surgically treated: PD
was diagnosed in only 2 and p-PD in 41 (21.1%)(Figure 1).
Ophthalmologists performed surgical therapy between
the 32nd and 34th weeks of gestation: laser-therapy,
argon laser 532 nm or diode laser 810 nm, andTable 3 Association between ROP and neonatal
parameters: logistic multivariate analysis
Parameters ROP No ROP Multivariate analysis
n newborns (%) OR p-value
GA ≤ 24 weeks 71 (75%) 24 (25%) 1.58 0.147
BW ≤ 750 g 168 (68%) 78 (32%) 1.63 0.053
PDA 167 (66%) 84 (34%) 1.21 0.455
IVH 118 (71%) 49 (29%) 2.10 0.003
Sepsis 134 (70%) 57 (30%) 1.43 0.135
BPD 142 (68%) 66 (32%) 1.32 0.249
EPO 147 (70%) 63 (30%) 2.93 < 0.0001cryotherapy. In all cases the laser-therapy was
performed; in 8 cases cryotherapy was attempted as add-
itional treatment. Four newborns with P-ROP required
vitrectomy following laser and cryotherapy (1.5% of all
newborn with ROP). All patients showed P-ROP in Zone
1. The outcome was evaluated as favorable in 251 non-
treated infants (94%) and in 68 (86.7%) of surgically
treated infants. Adverse outcomes occurred in 14 pa-
tients (3.3% of total population, 5.3% of infants with
ROP and 14.6% of surgically treated infants): 11 had bi-
lateral and 3 unilateral retinal detachment. All 14 had P-
ROP and underwent surgery (Figure 1).
Discussion
ROP widely affected extremely premature infants: the
occurrence of P-ROP represented the main risk factor for
surgical treatment. A considerable number of newborns
required surgery; laser therapy was mostly effective and
adverse outcomes were rare.
Our incidence data differ from those of the Cryotherapy
for Retinopathy of Prematurity Cooperative Group trial
and from those of the ETROP study [9,17]; these studies
reported a higher incidence of ROP but they were
conducted prior to the introduction of the current guide-
lines to prevent ROP [18].
Other studies showed results similar to ours [19-21].
The 2009 Vermont-Oxford Network Report showed an








































































Figure 1 Outcomes of the enrolled newborns.
Borroni et al. Italian Journal of Pediatrics 2013, 39:43 Page 5 of 7
http://www.ijponline.net/content/39/1/43In the multivariate analysis EPO therapy and IVH sig-
nificantly associated with the incidence of ROP; birth
weight showed only a borderline association. EPO ther-
apy was a risk factor for ROP, but not for P-ROP. Shah
et al. did not find any significant difference between
EPO therapy and the presence or severity of ROP [23].
Before the “EPO era”, blood transfusions were more
common in NICUs and some researchers considered
them as a risk factor for developing ROP [24,25]. Suk
et al. in a multiple regression model found that blood
transfusions were a significant independent risk factor
for the development of ROP. Currently it is not clear if
the therapy with EPO is advantageous compared to the
blood transfusions in treating anemic preterm infants
[26]. Schneider et al. showed that EPO therapy does not
increase the number and the severity of ROP cases,
while it may reduce the number of blood transfusionsTable 4 Association between P-ROP or treated newborn and
analysis
Parameters P - ROP OZ - ROP
n newborns (%)
GA≤ 24 weeks 37/71 (52.1%) 29/71 (40.8%)
Sepsis 60/134 (44.8%) 68/134 (50.7%)
BPD 57/142 (40.1%) 79/142 (55.6%)
Association between zones and significant neonatal par
Parameters Treatment No treatment
n newborns (%)
P - ROP 59/89 (66.3%) 35/142 (24.6%)
EG ≤24 weeks 33/89 (37.1%) 33/142 (23.2%)
BW≤ 750 g 69/89 (77.5%) 79/142 (55.6%)
Sepsis 54/89 (60.7%) 61/142 (42.9%)
Association between laser treatment and significant neonata[27]. Recently, in a mouse model of proliferative retin-
opathy, Chen et al. studied the role of EPO in suppres-
sion of retinal neovascularization; they proposed the
hypothetic intravitreal use of EPO in proliferative retin-
opathy [28].
In our study EPO administration was a factor involved
in the development of ROP, while it was not a factor
related to the severity of the disease: it was not signifi-
cantly associated to P-ROP and to the necessity of surgical
intervention. GA ≤ 24 weeks and sepsis were significant
risk factors for developing P- ROP. Even though gesta-
tional age was not directly related to the ROP, it triggered
P-ROP and therefore was one of the main causes of the
more severe type of the disease [29].
It is noteworthy that BPD was not associated with the
ROP, nor with the more aggressive kind of ROP, even
though the use of oxygen is particularly involved in ROPneonatal parameters: logistic univariate and multivariate
Univariate analysis Multivariate analysis
OR p-value OR p-value
2.43 0.002 2.30 0.011
2.35 0.002 2.64 0.002
2.01 0.020 1.53 0.182
ameters: univariate and multivariate logistic analysis
Univariate analysis Multivariate analysis
OR p-value OR p-value
7.84 < 0.0001 7.30 < 0.0001
1.95 0.024 0.97 0.946
2.75 0.001 2.07 0.054
2.36 0.003 1.58 0.188
l parameters: univariate and multivariate logistic analysis
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ate targets of oxygen saturation during oxygen-therapy,
both in the first weeks of life, when hyperoxia is danger-
ous, and also during the following weeks, when hypoxia
induces neovascularization. Some authors recommend
monitoring oxygen therapy on the basis of gestational age
and postnatal age: low-oxygen levels during early phases
of life and high levels in the later phases [30].
Our data on the risk factors for P-ROP are consistent
with the pathogenetic model recently proposed by Lee
and Damman: in their review they concluded that expos-
ure to perinatal infection/ inflammation is associated with
an increased risk for ROP. Circulating products of infec-
tion and/or inflammation might directly damage the de-
veloping retina; moreover inflammation and/or oxidative
stress might increase the risk of oxygen-associated ROP.
This means that prenatal, perinatal, and postnatal systemic
inflammation could sensitize the pre-ROP retina for
subsequent insults, setting the stage for what is now
called phase I and phase II of ROP pathogenesis. The
authors concluded that strategies for targeting inflam-
matory responses might help in reducing the risk for
ROP in extremely preterm infants [31].
In our study laser therapy was performed in all infants
requiring surgery; most of these infants had a P-ROP.
PD represented the main indicator for surgical interven-
tion as also reported in the ICROP study [11].
In almost all cases, the infants with ROP associated
with PD underwent surgical intervention; only 2 out of
75 newborns with PD were not treated with laser therapy.
Moreover, occurrence of p-PD represented an indication
for surgical intervention; although it was more evident in
the newborns affected by P-ROP than in OZ-ROP there
was probably an overtreatment in some cases. PD was
significantly higher in P-ROP than in OZ-ROP; therefore
infants with P-ROP underwent surgery more frequently
than infants with OZ-ROP. These observations confirm
the severity of P-ROP.
The percentage of children treated with laser therapy
in our population was equal to the percentage reported
in a Malaysian study and double the number reported in
a Swedish paper [20,21]. This variability of data may be
due to the differences of the populations involved. As
Darlow et al. in the Australian and New Zealand Neonatal
Network argued, the discrepancy between the data
reported in scientific literature may be attributed to a wide
variability in the classification of ROP [32]. For this reason
we classified the severity of ROP on the basis of zone and
presence of PD or p-PD. Our protocol allowed us to clas-
sify ROP disease more clearly without the inter-individual
differences of ophthalmologists.
Treatment was performed between the 32nd and the
34th weeks of gestation. The majority of surgically
treated infants had a favorable outcome; this isencouraging even though Ruth Axer-Siegel and coll.
reported 92.3% favorable outcomes following laser ther-
apy in a cohort of 100 neonates, which is slightly better
than our data [33]. It is important to underline that all
14 infants with an adverse outcome were ≤24 weeks ges-
tation, each one underwent almost one episode of sepsis
and was affected by P- ROP: this confirms once more
that P-ROP represents the most severe form of ROP and
it is associated with the worst short term outcome.
Conclusion
In order to prevent severe ROP in very preterm infants, a
multidisciplinary strategy is necessary: obstetricians should
prevent preterm births and intrauterine infections; neona-
tologists should reduce the occurrence of septic diseases
and should carefully monitor infant oxygen exposure. In
all NICUs, a pediatric ophthalmologist should periodically
evaluate all very preterm infants from the 28th day of post-
natal age. The follow-up of infants with Zone I and Zone
II posterior ROP needs to be particularly scrupulous since
these infants are at high risk of surgical intervention and
adverse outcome.
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